0000899243-21-004749.txt : 20210203
0000899243-21-004749.hdr.sgml : 20210203
20210203184212
ACCESSION NUMBER: 0000899243-21-004749
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210201
FILED AS OF DATE: 20210203
DATE AS OF CHANGE: 20210203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Peters Richard
CENTRAL INDEX KEY: 0001697628
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 21587939
MAIL ADDRESS:
STREET 1: MERRIMACK PHARMACEUTICALS, INC.
STREET 2: ONE KENDALL SQUARE, SUITE B7201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: YUMANITY THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001445283
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 GUEST STREET
STREET 2: SUITE 4410
CITY: BOSTON
STATE: MA
ZIP: 02135
BUSINESS PHONE: 617-409-5300
MAIL ADDRESS:
STREET 1: 40 GUEST STREET
STREET 2: SUITE 4410
CITY: BOSTON
STATE: MA
ZIP: 02135
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20140813
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC
DATE OF NAME CHANGE: 20080916
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-01
0
0001445283
YUMANITY THERAPEUTICS, INC.
YMTX
0001697628
Peters Richard
C/O YUMANITY THERAPEUTICS, INC
40 GUEST STREET, SUITE 4410
BOSTON
MA
02135
1
1
0
0
President & CEO
Common Stock
2021-02-01
4
A
0
60943
0.00
A
60943
D
Stock Option (Right to Buy)
17.89
2021-02-01
4
A
0
120000
0.00
A
2031-01-31
Common Stock
120000
120000
D
Stock Option (Right to Buy)
17.89
2021-02-01
4
A
0
60944
0.00
A
2031-01-31
Common Stock
60944
60944
D
The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in four equal annual installments over four years following July 1, 2020.
This option shall vest and become exercisable in 48 equal monthly installments over four years following the Grant Date.
This option shall vest and become exercisable in 48 equal monthly installments over four years following July 1, 2020.
/s/ Marie Epstein, Attorney-in-Fact
2021-02-03